On February 28, the "China's Top 30 ESG Listed Companies in Sci-Tech Innovation (2024)" list was unveiled. Sino Biopharm stood out from 972 companies for its continuous investment in scientific and technological innovation and outstanding ESG performance, becoming one of the 30 listed companies alongside several industry leaders in China. The list was selected by authoritative institutions including China Central Television (CCTV), the State-owned Assets Supervision and Administration Commission of the State Council, the All-China Federation of Industry and Commerce, the National Economic Research Think Tank of the Chinese Academy of Social Sciences, and the China Enterprise Reform and Development Society, and was officially released concurrently with the "Sci-Tech Innovation ESG Action Report (2024)".

Sino Biopharm has always adhered to the development vision of "To be a leading global pharmaceutical company through delivering innovative therapies for patients", deeply integrating ESG with corporate strategy and operations. With "innovation" and "internationalization" as its strategic wings, it drives innovation through a digital strategy, contributing to the health and well-being of patients worldwide. As one of the first pharmaceutical companies in China to officially integrate DeepSeek-R1, Sino Biopharm is actively exploring the deep integration of its digital strategy with AI technology. While continuously increasing R&D investment, it utilizes digital technology to comprehensively enhance operational and R&D efficiency. To date, the Group's innovative drug research has continued to yield fruitful results, and the proportion of revenue from innovative drugs has continued to increase. At the same time, the effectiveness of the Group's ESG construction is gradually becoming apparent. The ESG management system is continuously improving, and the management of key ESG issues is comprehensively advancing. Significant progress has been made in areas of "Cure, Accessible, Relationship, and Environmental", providing strong support for the effective implementation of the Group's comprehensive innovation and internationalization strategies.

Being selected for the "China's Top 30 ESG Listed Companies in Sci-Tech Innovation (2024)" list represents the full affirmation by authoritative institutions of Sino Biopharm's leadership in technological innovation, deepening of ESG practices, and empowerment of new quality productive forces through responsible innovation. In the future, Sino Biopharm will continue to focus on technological innovation, consistently practice the concept of sustainability, actively promote the high-quality sustainable development of the industry, strive to become a leading global pharmaceutical company, and benefit patients worldwide with health technology.